IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients.
Oncotarget
Di Salvatore, Mariantonietta M; Pietrantonio, Filippo F; Orlandi, Armando A; Del Re, Marzia M; Berenato, Rosa R; Rossi, Ernesto E; Caporale, Marta M; Guarino, Donatella D; Martinetti, Antonia A; Basso, Michele M; Mennitto, Roberta R; Santonocito, Concetta C; Mennitto, Alessia A; Schinzari, Giovanni G; Bossi, Ilaria I; Capoluongo, Ettore E; Danesi, Romano R; de Braud, Filippo F; Barone, Carlo C
Recurrent inactivating RASA2 mutations in melanoma.
Nature Genetics
Arafeh, Rand R; Qutob, Nouar N; Emmanuel, Rafi R; Keren-Paz, Alona A; Madore, Jason J; Elkahloun, Abdel A; Wilmott, James S JS; Gartner, Jared J JJ; Di Pizio, Antonella A; Winograd-Katz, Sabina S; Sindiri, Sivasish S; Rotkopf, Ron R; Dutton-Regester, Ken K; Johansson, Peter P; Pritchard, Antonia L AL; Waddell, Nicola N; Hill, Victoria K VK; Lin, Jimmy C JC; Hevroni, Yael Y; Rosenberg, Steven A SA; Khan, Javed J; Ben-Dor, Shifra S; Niv, Masha Y MY; Ulitsky, Igor I; Mann, Graham J GJ; Scolyer, Richard A RA; Hayward, Nicholas K NK; Samuels, Yardena Y